

# ACTA MEDICINAE 5/2012 VNITŘNÍ LÉKAŘSTVÍ

## Kompletní literatura

- 2 **Využití moderní diabetologické léčby v ordinaci interního lékaře**  
prof. MUDr. Martin Haluzík, DrSc. III. interní klinika 1. LF UK a VFN, Praha
- 2 **Využití léčebné enterální výživy v gastroenterologii**  
MUDr. Milan Dastych | MUDr. Michal Šenkyřík  
Interní gastroenterologická klinika, FN Brno a LF MU
- 3 **Crizotinib jako další molekulárně cílený lék nemalobuněčného karcinomu plic**  
prof. MUDr. Miloš Pešek, CSc. Klinika TRN FN Plzeň
- 4 **Lékový profil: Egiramlon**  
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
- 4 **Antiagregační léčba 2012**  
doc. MUDr. Jiří Špác, CSc. | MUDr. Bohuslav Kianička, Ph.D.  
2. interní klinika LF MU a FN u sv. Anny v Brně
- 4 **Léčba candesartanem u kardiovaskulárních onemocnění**  
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
- 5 **Metabolický syndrom po infarktu myokardu**  
doc. MUDr. Eliška Sovová, Ph.D. I. interní klinika – kardiologická, Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace, LF UP v Olomouci a FN Olomouc
- 6 **Obtížně léčitelný případ revmatoidní artritidy s mimokloubními projevy a mnohočetnou intolerancí léčby**  
doc. MUDr. Petr Bradna, CSc. | MUDr. Tomáš Soukup, Ph.D. | MUDr. Jan Tomš  
II. interní gastroenterologická klinika, Subkatedra revmatologie katedry interních oborů UK v Praze, LF a FN Hradec Králové
- 6 **Lékový profil: Spiriva Respimat**  
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
- 7 **Dabigatran etexilát – orální inhibitor trombinu**  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
- 7 **Léčba periferní neuropatické bolesti – možnosti lokální terapie**  
MUDr. Jan Lejško ARK, Centrum léčby bolesti, FN Plzeň
- 8 **Kardiometabolické následky běžné dětské obezity**  
MUDr. Zlatko Marinov Dětské obezitologické centrum, FN Motol a 2. LF UK, Praha
- 8 **Fomeptizol – antidotum při otravě metanolem a etylenglykolem**  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

# Využití moderní diabetologické léčby v ordinaci interního lékaře

prof. MUDr. Martin Haluzík, DrSc. III. interní klinika 1. LF UK a VFN, Praha

- 1 O'Rahilly, S.: Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. *BMJ*, 1997, 314, s. 955–959.
- 2 Fonseca, V. A.: Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. *The American Journal of Cardiology*, 2011, 108, s. 52B–58B.
- 3 Skyler, J. S. – Bergenstal, R. – Bonow, R. O., et al.: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. *Journal of the American College of Cardiology*, 2009, 53, s. 298–304.
- 4 Holman, R. R. – Paul, S. K. – Bethel, M. A., et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. *The New England Journal of Medicine*, 2008, 359, s. 1577–1589.
- 5 Inzucchi, S. E. – Bergenstal, R. M. – Buse, J. B., et al.: Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2012, 35, s. 1364–1379.
- 6 Deacon, C. F.: Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review. *Diabetes, Obesity & Metabolism*, 2011, 13, s. 7–18.
- 7 Haluzík, M. – Svačina, Š.: *Inkretinová léčba diabetu*. Praha, Mladá Fronta, 2010.
- 8 Drucker, D. J. – Sherman, S. I. – Gorelick, F. S., et al.: Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. *Diabetes Care*, 2010, 33, s. 428–433.
- 9 Baetta, R. – Corsini, A.: Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. *Drugs*, 2011, 71, s. 1441–1467.
- 10 Abu-Hamdah, R. – Rabiee, A. – Meneilly, G. S., et al.: Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. *The Journal of Clinical Endocrinology and Metabolism*, 2009, 94, s. 1843–1852.
- 11 Haluzík, M. – Rychlík, I., et al.: *Léčba diabetu u pacientů s onemocněním ledvin a jater*. Praha, Mladá fronta, 2012.

## Využití léčebné enterální výživy v gastroenterologii

MUDr. Milan Dastych | MUDr. Michal Šenkyřík

Interní gastroenterologická klinika, FN Brno a LF MU

- 1 O'Morain, C. – Segal, A. W. – Levi, A. J.: Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. *Br Med J*, 1984, 288, s. 1859–1862.
- 2 Kelly, D. – Fleming, R.: Nutritional considerations in inflammatory bowel diseases. *Gastroenterology Clinics of North America*, 1995, 24, s. 597–611.
- 3 Lochs, H. – Steinhardt, H. J. – Kleuas-Weitz, M., et al.: Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study IV. *Gastroenterology*, 1991, 101, s. 881–888.
- 4 Griffiths, A. M.: Inflammatory Bowel Disease. *Nutrition*, 1998, 14, s. 788–791.
- 5 Griffiths, A. M. – Ohlson, A. – Herman, P., et al.: Meta analysis of enteral nutrition as primary therapy of active Crohn's disease. *Gastroenterology*, 2005, 108, s. 1056.
- 6 Seidman, E. – Griffiths, A. M. – Jones, A., et al.: Efficacy of a semielemental diet versus prednisone in treatment of acute Crohn's disease in children. A randomized controlled trial. *Gastroenterology*, 1993, 104, s. 778.
- 7 Heuschkel, R. – Walker-Smith, J.: Enteral nutrition in inflammatory bowel disease of childhood. *JPEN*, 1999, 23, s. 29–32.
- 8 Zachos, M. – Tonderu, M. – Griffiths, A. M.: Enteral nutritional therapy for inducing remission of Crohn's disease. *Cochrane Database Syst Rev*, 2001, 3, s. 542.
- 9 Ludvigsson, J. F. – Krantz, M. – Bodin, L., et al.: Elemental versus polymeric enteral nutrition in pediatric Crohn's disease: a multicentre randomized controlled trial. *Acta Paediatr*, 2004, 93, s. 327–335.
- 10 Campos, F. G. – Waitzberg, D. L. – Teixeira, M. G., et al.: Pharmacological nutrition in inflammatory bowel diseases. *Nutr Hosp*, 2003, 18, s. 57–64.
- 11 Goh, J. – Morain, C. A.: Review article: nutrition and adult inflammatory bowel disease. *Aliment Pharmacol Ther*, 2003, 17, s. 307–320.
- 12 Cabre, E. – Gassul, M. A.: Nutrition in inflammatory bowel disease: impact on disease and therapy. *Curr Opin Gastroenterol*, 2001, 17, s. 342–349.
- 13 Sobotka, L.: *Basics in Clinical Nutrition*. Praha, Galén, 2004, s. 339.
- 14 Dickerson, R. N. – Vehe, K. L. – Kuklen, J. L. – Feurer, I. D.: Resting energy expenditure in patients with pancreatitis. *Crit Care Med*, 1991, 19, s. 484–490.
- 15 O'Keefe, S. J. – McClave, S. A.: Feeding the injured pancreas. *Gastroenterology*, 2005, 129, s. 1129–1130.
- 16 Meier, R. – Ockenga, J. – Pertkiewicz, M. – Pap, A. – Milinic, N. – Mañe, J., et al.: ESPEN Guidelines on Enteral Nutrition: Pancreas. *Clin Nutr*, 2006, 25, s. 275–284.
- 17 Meier, R. F. – Beglinger, C.: Nutrition in pancreatic diseases. *Best Pract Res Clin Gastroenterol*, 2006, 20, s. 507–529.
- 18 Sitzmann, J. V. – Steinborn, P. A. – Zinner, M. J. – Cameron, J. L.: Total parenteral nutrition and alternate energy substrates in treatment of severe acute pancreatitis. *Surg Gynecol Obstet*, 1989, 168, s. 311–317.
- 19 Hill, G. L.: Body composition research: Implication for the practise of clinical nutrition. *Parental Enteral Nutr*, 1992, 16, s. 197–218.
- 20 O'Keefe, S. J. – Lee, R. B. – Anderson, F. P. – Gennings, C. – Abou-Asi, S. – Clore, J., et al.: Physiological effects of enteral and parenteral feeding on pancreaticobiliary secretion in humans. *Am J Physiol Gastrointest Liver Physiol*, 2003, 284, s. G27–36.
- 21 O'Keefe, S. J. – Lee, R. B. – Li, J. – Zhou, W. – Stoll, B. – Dang, Q.: Trypsin and splanchnic protein turnover during feeding and fasting in human subjects. *Am J Physiol Gastrointest Liver Physiol*, 2006, 290, s. G213–221.
- 22 Vu, M. K. – van der Veek, P. P. – Frölich, M. – Souverein, J. H. – Biemond, I. – Lamers, C. B. – Masclee, A. A.: Does jejunal feeding activate exocrine pancreatic secretion? *Eur J Clin Invest*, 1999, 29, s. 1053–1059.
- 23 Kaustik, N. – Pietraszewski, M. – Holst, J. J. – O'Keefe, S. J.: Enteral feeding without pancreatis stimulation. *Pancreas*, 2005, 31, s. 353–359.
- 24 Marik, P. E. – Zaloga, G. P.: Meta-analysis of parenteral nutrition versus enteral nutrition in patients with acute pancreatitis. *BMJ*, 2004, 328, s. 1407.
- 25 Vidon, N. – Hecketsweiler, P. – Buttel, J., et al.: Effect of continuous jejunal perfusion of elemental and komplex nutritional solutions on pancreatic enzyme secretion in human subjects. *Gut*, 1978, 19, s. 194–198.
- 26 Konturek, S. J. – Tasler, J. – Obtulowicz, W.: Localization of cholecystokinin release in intestine of the dog. *Am J Physiol*, 1972, 222, s. 19–20.

# Crizotinib jako další molekulárně cílený lék nemalobuněčného karcinomu plic

prof. MUDr. Miloš Pešek, CSc. Klinika TRN FN Plzeň

- 1 Bowle, D. W. – Weickhardt, A. J. – Doebele, R. C. – Camidge, D. R. – Mámeno, A.: Crizotinib for the treatment of patients with advanced non-small cell lung cancer. *Drugs of Today*, 2012, 48 (4), s. 271–282.
- 2 Camidge, D. R. – Doebele, R. C.: Treating ALK-positive lung cancer – early successes and future challenges. *Nat Rev Clin Oncol*, 2012, 9, s. 268–277.
- 3 Camidge, D. R. – Kono S. A. – Lu, X., et al.: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. *J Thorac Oncol*, 2011, 6 (4), s. 774–780.
- 4 Forde, P. M. – Rudin, Ch. M.: Crizotinib in the treatment of non-small-cell lung cancer. *Expert Opin. Pharmacother*, 2012, 13 (8), s. 1195–1201.
- 5 Inamura, K. – Takeuchi, K. – Togashi, Y., et al.: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. *J Thorac Oncol*, 2008, 3 (1), s. 13–17.
- 6 Dong-Wan, K. – Myung-Ju, A. – Yuankai, S. – De Pas, T. M. – Pan-Chyr, Y. – Riely, G. J. – Crinò, L. – Svand, T. L. – Xiaoqing, L. – Ji-Youn, H. – Salgia, R. – Moro-Sibilot, D., et al.: Výsledky mezinárodní studie fáze II crizotinibu u pokročilého nemalobuněčného karcinomu plic (NSCLC) s pozitivním ALK. 48. výroční zasedání ASCO Annual Meeting 2012, 1.–5. 6. 2012, *J Clin Oncol*, červenec 2012, ročník 4, speciální číslo, abstrakt, s. 135–136.
- 7 Kim, D. W. – Blackhall, F. – Soria, J. C. – Salomon, B. – Camidge, D. R. – Crinò, L. – Riely, G. J. – Bottomley, A. – Tassell, V. – Polli, A. – Shaw, A.: A Global Phase 2 Study Including Efficacy, Safety, and Patient-reported Outcomes with Crizotinib in Patients with ALK-positive Non-small Cell Lung Cancer. ECCO-ESMO 2011, European Multidisciplinary Cancer Congress, Stockholm, Švédsko, 23.–27. 7. 2011, abstrakt 9084.
- 8 Kimura, H. – Nkajima, T. – Takeuchi, K. – Soda, M. – Mano, H. – Iizasa, T. – Matsui, Y. – Tshibo, M. – Shingyoji, M. – Itakura, M. – Itami, M. – Ikebe, D. – Yokoi, S. – Kageyama, H. – Ohira M. – Nakagawara, A.: ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. *Lung Cancer*, 2012, 75, s. 66–72.
- 9 Lee, J. O. – Kim, T. M. – Lee, S. H., et al.: Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. *J Thorac Oncol*, 2011, 6 (9), s. 1474–1480.
- 10 Martelli, M. P. – Sluzi, G. – Hernandez, L., et al.: AML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. *Am J Pathol*, 2009, 174 (2), s. 661–670.
- 11 McDermott, U. – Lafrate, A. J. – Gray, N. S., et al.: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. *Cancer Res*, 2008, 68 (9), s. 3389–3395.
- 12 Mologni, L.: Inhibitors of the anaplastic lymphoma kinase. *Expert Opin Investig Drugs*, 2012, 21 (7), s. 985–994.
- 13 Otterson, G. A. – Riely, G. J. – Shaw, A. Tsang-Crinò, L. – Dong-Wan, K. – Martins, R. – Salgia, R. – Zhou, C. – Salomon, B. J. – Wilner, K. D. – Polli, A. – Tang, Y. – Bartlett, C. H. – Sai-Hong, I. O.: Klinické charakteristiky pacientů s NSCLC s ALK + léčených crizotinibem po progresi onemocnění (PD): potenciální význam pro léčbu. 48. výroční zasedání ASCO Annual Meeting 2012, 1.–5. 6. 2012, *J Clin Oncol*, červenec 2012, ročník 4, speciální číslo, abstrakt, s. 137.
- 14 Sai-Hong, I. O.: Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. *Drug Design, Development and Therapy*, 2011, 5, s. 471–485.
- 15 Pešek, M. – Grossmann, P. – Mukenšabl, P. – Minárik, M.: První zkušenosti s vyšetřováním zlomu genu ALK (anaplastické lymfomové kinázy) a s podáním crizotinibu u vybraných nemocných s nemalobuněčnými karcinomy plic (NSCLC). *Studia Pneumologica*, 2012, 72 (3), s. 159–162.
- 16 Peters, S. – Adjei, A. A.: MET: a promising anticancer therapeutic target. *Nat Rev Clin Oncol*, 2012, 9, s. 314–326.
- 17 Rodig, S. J. – Mino-Kenudson, M. – Dacic, S., et al.: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. *Clin Cancer Res*, 2009, 15 (16), s. 5216–5223.
- 18 Shaw, A. T. – Camidge, D. R. – Engelman, J. A. – Salomon, B. J. – Klak, E. L. – Clark, J. W. – Salgia, R. – Shapiro, G. – Bang, Y.-J. – Tan, W. – Tye, L. – Wilner, K. D. – Stehenson, P. – Varela-Garcia M. – Bergethson, K. – lafrate, A. J. – Sai-Hong, I. O.: Klinická účinnost crizotinibu u pokročilého nemalobuněčného karcinomu plic (NSCLC) s přeskupením genu ROS1. 48. výroční zasedání ASCO Annual Meeting 2012, 1.–5. 6. 2012, *J Clin Oncol*, červenec 2012, ročník 4, speciální číslo, abstrakt s. 131–132.
- 19 Shaw, A. T. – Trap, B. Y. – Mino-Kenudson, M., et al.: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol*, 2009, 27 (26), s. 4247–4253.
- 20 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- 21 Salomon, B. – Chiappori, A. – Lamb, A. – Gawlicki, M. C. – Kim, D. W. – Park, K. – Salgia, R. – Wilner, K. – Reisman, A. – Petersen, J.: Preliminary Characterization of Visual Events Reported by Patients Receiving Crizotinib for the Treatment of Advanced ALK-positive Non-small Cell Lung Cancer. ECCO-ESMO 2011, European Multidisciplinary Cancer Congress, Stockholm, Švédsko, 23.–27. 7. 2011, abstrakt 3030.
- 22 Sun, Y. – Ren, Y. – Fang, Z., et al.: Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. *J Clin Oncol*, 2010, 28 (30), s. 4616–4620.
- 23 Takahashi, T. – Sonobe, M. – Kobayashi, M., et al.: Clinicopathologic features of non-small cell lung cancer with EML4-ALK fusion gene. *Ann Surg Oncol*, 2010, 17, s. 889–897.
- 24 Takeda, M. – Okamoto, I. – Sakai, K. – Tahala, K. – Terasnima, M. – Nishio, K. – Nakagawa, K.: Successful Long-Term Treatment With Pemetrexed of NSCLC Associated With EML4-ALK and Low Thymidylate Synthase Expression. *Clin Lung Cancer*, 2012, 13 (2), s. 157–159.
- 25 ÚZIS ČR: Zdravotnická statistika: Novotvary 2009 ČR. ÚZIS ČR, NOR ČR, 2012.
- 26 West, L. – Vidwans, S. J. – Campbell, N. P. – Shrager, J. – Simon, G. R. – Bueno, R. – Denis, P. A. – Otterson, G. A. – Salgia, R.: A Novel Classification of Lung Cancer into Molecular Subtypes. *PLoS ONE*, 2012, 7 (2), e31906, doi: 10.1371/journal.pone.0031906.
- 27 Wong, D. W. – Leung, E. L. – So, K. K. – Tam, I. Y. – Sihoe, A. D. – Cheng, L. C. – Ho, K. K. – Au, J. S. – Chung, L. P. – Pik Wong, M.: University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer*, 2009, 115 (8), s. 1723–1733.
- 28 Yang, J. – Zhang, X. – Su, J. – Chen, H. – Tian, H. – Juany, Y. – Xu, C. – Wu, Y. L.: Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. *Journal of Clin Oncol*, 2011, ASCO Annual Meeting Proceedings (post-Meeting Edition), 29 (15), dopl., 2011, abstrakt 10517.
- 29 Zhang, X. – Zhang, S. – Yang, X., et al.: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. *Mol Cancer*, 2010, 9, s. 188.

# Lékový profil: Egiramlon

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

- 1 **Abernethy, D. R.:** Pharmacokinetics and pharmacodynamics of amlodipine. *Cardiology*, 1992, 80, dopl. 1, s. 31–36.
- 2 **Bangalore, S. – Kamalakkannan, G. – Parkar, S. – Messerli, F. H.:** Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- 3 **Wald, D. S. – Law, M. – Morris, J. K. – Bestwick, J. P. – Wald, N. J.:** Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 4 **Corrao, G. – Nicotra, F. – Parodi, A., et al.:** Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. *Hypertension*, 2011, 58, s. 566–572.
- 5 **Miranda, R. D. – Mion, D. Jr. – Rocha, J. C., et al.:** An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. *Clin Ther*, 2008, 30, s. 1618–1628.

## Antiagregační léčba 2012

doc. MUDr. Jiří Špác, CSc. | MUDr. Bohuslav Kianička, Ph.D.

2. interní klinika LF MU a FN u sv. Anny v Brně

- 1 **Antithrombotic Trialists' Collaboration:** Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*, 2002, 324 (7329), s. 71–86.
- 2 **Raju, N. – Sobieraj-Teague, M. – Hirsh, J., et al.:** Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. *The American Journal of Medicine*, 2011, 124, s. 621–629.
- 3 **Andersson, C. – Lyngbæk, S. – Nguyen, C. D., et al.:** Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. *JAMA*, 2012, 308, s. 882–889.
- 4 **Brandt, J. T. – Payne, C. D. – Wiviopp, S. D., et al.:** A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. *Am Heart J*, 2007, 153, 1, 66.e9–66.e16.
- 5 **Mousa, S. A. – Jeske, W. P. – Fareed, J.:** Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. *Clin Appl Thromb Hemost*, 2010, 16, 2, s. 170–176.
- 6 **Wiviott, S. D. – Braunwald, E. – McCabe, C. H., et al.:** Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*, 2007, 357, s. 2001–2015.
- 7 **Roe, M. T. – Armstrong, P. W. – Fox, K. A. A., et al.:** Prasugrel versus clopidogrel for ACS patients managed without revascularization. *N Engl J Med*, 2012, doi: 10.1056/NEJMoa1205512.
- 8 **Wallentin, L. – Becker, R. C. – Budaj, A., et al.; PLATO Investigators:** Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *New Engl J Med*, 2009, 361 (11), s. 1045–1057.
- 9 **Rao, S., for the INNOVATE PCI investigators.** A randomized, double-blind, active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel), a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. European Society of Cardiology 2010, kongres, 2010, Stockholm, Švédsko.
- 10 **Morrow, D. A. – Braunwald, E. – Bonaca, M. P., et al.:** Vorapaxar in the secondary prevention of atherothrombotic events. *New Engl J Med*, 2012, 366, s. 1404–1413.
- 11 **Faxon, D. – Eikelboom, J. – Berger, P., et al.:** Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. *Thromb Haemost*, 2011, 106, 4, s. 572–584.

## Léčba candesartanem u kardiovaskulárních onemocnění

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

- 1 **Elmfeldt, D. – George, M. – Hubner, R. – Olofsson, B.:** Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. *J Hum Hypertens*, 1997, 11, dopl. 2, S49–S53.
- 2 **Philipp, T. – Letzel, H. – Arens, H. J.:** Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. *J Hum Hypertens*, 1997, 11, dopl. 2, S67–S68.
- 3 **McInnes, G. T. – O'Kane, K. P. – Jonker, J. – Roth, J.:** The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. *J Hum Hypertens*, 1997, 11, dopl. 2, S75–S80.
- 4 **Lithell, H. – Hansson, L. – Skoog, I., et al.:** The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *J Hypertens*, 2003, 21, s. 875–886.
- 5 **Zanchetti, A. – Elmfeldt, D.:** Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE)—a review. *Blood Press*, 2006, 15, s. 71–79.
- 6 **Feghali, R. E. – Nisse-Durgeat, S. – Asmar, R.:** Effect of candesartan cilexetil on diabetic and non-diabetic hypertensive patients: metaanalysis of five randomized double-blind clinical trials. *Vasc Health Risk Manag*, 2007, 3, s. 165–171.
- 7 **Meredith, P. A. – Murray, L. S. – McInnes, G. T.:** Comparison of the efficacy of candesartan and losartan: a metaanalysis of trials in the treatment of hypertension. *J Hum Hypertens*, 2010, 24, s. 525–531.
- 8 **Zhenfeng, Z. – Huilan, S. – Junya, J. – Dong, L. – Shan, L.:** A systematic review and metaanalysis of candesartan and losartan in the management of essential hypertension. *J Renin Angiotensin Aldosterone Syst*, 2011, 12, s. 365–374.
- 9 **Zanchetti, A. – Omboni, S.:** Comparison of candesartan versus enalapril in essential hypertension. Italian Candesartan Study Group. *Am J Hypertens*, 2001, 14, s. 129–134.
- 10 **Granger, B. B. – Swedberg, K. – Ekman, I., et al.:** Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. *Lancet*, 2005, 366, s. 2005–2011.
- 11 **McMurray, J. J. – Young, J. B. – Dunlap, M. E., et al.:** Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. *Am Heart J*, 2006, 151, s. 985–991.

- 12 Granger, C. B. – McMurray, J. J. – Yusuf, S., et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet*, 2003, 362, s. 772–776.
- 13 Yusuf, S. – Pfeffer, M. A. – Swedberg, K., et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet*, 2003, 362, s. 777–781.
- 14 Pfeffer, M. A. – Swedberg, K. – Granger, C. B., et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*, 2003, 362, s. 759–766.

## Metabolický syndrom po infarktu myokardu

doc. MUDr. Eliška Sovová, Ph.D. I. interní klinika – kardiologická, Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace, LF UP v Olomouci a FN Olomouc

- 1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. *Circulation*, 2002, 106, s. 3143–3421.
- 2 International Diabetes Federation: *The IDF consensus worldwide definition of the metabolic syndrome* [on-line, vyhledáno 21. 9. 2012]. Dostupné z: [www.idf.org/webdata/docs/Metac\\_syndrome\\_def.pdf](http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf).
- 3 Grundy, S. M. – Brewer, H. B. – Cleeman, J. I., et al.: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation*, 2004, 109 (3), s. 433–438.
- 4 Lakka, H. M. – Laaksonen, D. E. – Lakka, T. A., et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle age men. *JAMA*, 2002, 288, s. 2709–2716.
- 5 Malik, S. – Wong, N. D. – Franclin, S. S., et al.: Impact of metabolic syndrome on mortality for coronary heart disease, cardiovascular disease and all causes in United States adults. *Circulation*, 2004, 110, s. 1245–1250.
- 6 Keller, M. – Gabriel, P. – Ravisy, J., et al.: Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. *Arch Int Med*, 2005, 165, s. 1192–1198.
- 7 Reiner, Ž. – Catapano, A. L. – De Backer, G., et al.: ESC/EAS guidelines for the management of dyslipidaemias. *European Heart Journal*, 2011, 32, s. 1769–1818.
- 8 Kastorini, C. M. – Milionis, H. J. – Esposito, K., et al.: The effect of Mediterranean diet on metabolic syndrome and its components. *J Am Coll Cardiol*, 2011, 57, s. 1299–1313.
- 9 Mitka, M.: Where the elite meet to eat. *JAMA*, 2000, 284, s. 817–818.
- 10 Singh, R. B. – Dubnov, G. – Niaz, M. A., et al.: Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high-risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. *Lancet*, 2002, 360, s. 1455–1461.
- 11 <http://www.oldwayspt.org/>, vyhledáno 21. 9. 2012.
- 12 Crowe, F. L. – Roddam, A. W. – Key, T. J., et al.: Fruit and vegetable intake and mortality from ischemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. *European Heart Journal*, 2011, 32, s. 1235–1243.
- 13 Simopoulos, A. P.: Omega 3 fatty acids in the prevention management of cardiovascular disease. *Can J Physiol Pharmacol*, 1997, 75, s. 234–239.
- 14 Burr, M. L. – Fehily, A. M. – Gilbert, L. F., et al.: Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet*, 1989, 2, s. 757–761.
- 15 Gissi- prevenzione investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. *Lancet*, 1999, 354, s. 447–455.
- 16 Yokoyama, M. – Origasa, H. – Matsuzaki, M., et al.: Effects of eicosapentaenoic acid on major events in hypercholesterolaemic patients (JELIS). a randomised open label blinded endpoint analysis. *Lancet*, 2007, 369, s. 1090–1098.
- 17 Piepoli, M. F. – Corra, U. – Benzen, W., et al.: Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training. *Eur Heart J*, 2010, 31, s. 1967–1974.
- 18 Soga, Y. – Yokoi, H. – Amemiya, K., et al.: Safety and efficacy of exercise training after coronary stenting in patients with stable coronary artery disease. *Circ J*, 2011, 75 (10), s. 2379–2386.
- 19 Dahabreh, I. J. – Paulu, J. K.: Association of episodic physical and sexual activity with triggering of acute cardiac events. Systematic review and meta analysis. *JAMA*, 2011, 305, s. 1225–1233.
- 20 Aldcroft, S. A. – Taylor, N. F. – Blackstock, F. C., et al.: Psychoeducational rehabilitation for health behavior change in coronary artery disease: a systematic review of controlled trials. *J Cardiopulm Rehabil Prev*, 2011, 31 (5), s. 273–281.
- 21 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Journal of Hypertension*, 2007, 25 (6), s. 1105–1187.
- 22 Widimský, J. – Cífková, R. – Špinar, J., et al.: Doporučení diagnostických a léčebných postupů u arteriální hypertenze. *Cor Vasa*, 2008, 50 (1), s. K5–K22.
- 23 Fagard, R. H. – Van Den Broeke, C. – De Cort, P.: Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. *J Hum Hypertens*, 2005, 19, s. 801–807.
- 24 Rodbard, H. W. – Jellinger, P. S. – Davidson, J. A., et al.: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. *Endocr Pract*, 2009, 15 (6), s. 540–559.
- 25 Pelikánová, T.: Diabetes mellitus a kardiovaskulární onemocnění. *Cor Vasa*, 2011, 53, s. 4–5.
- 26 Vaverková, H. – Soška, V. – Rosolová, H., et al.: Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti. *Cor Vasa*, 2007, 49 (3), s. K73–K86.
- 27 Young, T. – Palta, M. – Dempsey, J., et al.: The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med*, 1993, 328, s. 1230–1235.
- 28 Pack, A. I. – Gislason, T.: Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. *Prog Cardiovasc Dis*, 2009, 51 (5), s. 434–451.
- 29 Punjabi, N. M. – Sahar, E. – Renine, S., et al.: Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. *Am J Epidemiol*, 2004, 160 (6), s. 521–530.
- 30 Coughlin, S. R. – Mawdsley, L. – Mugarza, J. A., et al.: Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *Eur Heart J*, 2004, 25 (9), s. 735–741.
- 31 Somers, V. K. – White, D. P. – Amin, R., et al.: Sleep apnea and cardiovascular disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institute of Health). *J Am Coll Cardiol*, 2008, 52, s. 686–717.

- 32 Bradley, T. G. – Floras, J. S.: Obstructive sleep apnoea and its cardiovascular consequences. *Lancet*, 2009, 373, s. 82–93.
- 33 Newman, A. B. – Nieto, F. J. – Guidry, U., et al.: Relation of sleep disordered breathing to cardiovascular disease risk factors. *Am J Epidemiol*, 2001, 154 (1), s. 50–59.
- 34 Lam, J. – Ip, M.: An update on obstructive sleep apnea and the metabolic syndrome. *Curr Opin Pulm Med*, 2007, 13 (6), s. 484–489.
- 35 Tkacova, R. – Dorkova, Z. – Molcanyiova, A., et al.: Cardiovascular risk and insulin resistance in patients with obstructive sleep apnea. *Med Sci Monit*, 2008, 14 (9), s. 438–444.
- 36 Sahar, E. – Whitney, C. W. – Renine, S., et al.: Sleep disordered breathing and cardiovascular disease. Cross sectional results of the Sleep Heart Health Study. *Am J Respir Crit Care Med*, 2001, 163 (1), s. 19–25.
- 37 Peker, Y. – Hedner, J. – Kraiczi, H., et al.: Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. *Am J Respir Crit Care Med*, 2000, 162, s. 81–86.
- 38 Lee, C. H. – Khoo, S. M. – Tai, B. C., et al.: Obstructive sleep apnea in patients admitted for acute myocardial infarction. Prevalence, predictors, and effect on microvascular perfusion. *Chest*, 2009, 135 (6), s. 1488–1495.
- 39 Demir, T. – Demir, O. – Kefi, A., et al.: Prevalence of erectile dysfunction in patients with metabolic syndrome. *Int J Urol*, 2006, 13 (4), s. 385–388.
- 40 Pacana, T. – Fuchs, M.: The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. *Clin Liver Dis*, 2012, 16 (3), s. 599–613.

## Obtížně léčitelný případ revmatoidní artritidy s mimokloubními projevy a mnohočetnou intolerancí léčby

doc. MUDr. Petr Bradna, CSc. | MUDr. Tomáš Soukup, Ph.D. | MUDr. Jan Tomš  
 II. interní gastroenterologická klinika, Subkatedra revmatologie katedry  
 interních oborů UK v Praze, LF a FN Hradec Králové

- 1 Smolen, J. S. – Aletaha, D. – Bijlsma, J. W. J., et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis*, 2010, 69, s. 631–637.
- 2 Felson, D. T. – Smolen, J. S. – Wells, G., et al.: American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. *Ann Rheum Dis*, 2011, 70, s. 404–413.
- 3 Vastesaeger, N. – Xu, S. – Aletaha, D., et al.: A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. *Rheumatology (Oxford)*, 2009, 48 (9), s. 1114–1121.
- 4 Scrivero, E. – Conti, F. – Spinelli, R., et al.: Switching between TNF $\alpha$  antagonists in rheumatoid arthritis: personal experience and review of the literature. *Reumatismo*, 2009, 61 (2), s. 107–117.
- 5 Markenson, J. A. – Gibofsky, A. – Palmer, W. R., et al.: Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. *J Rheumatol*, 2011, 38 (7), s. 1273–1281.
- 6 Bartelds, G. M. – Kriekkaert, C. L. – Nurmohamed, M. T., et al.: Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. *JAMA*, 2011, 305 (14), s. 1460–1468.
- 7 Gomez-Reino, J. – Maneiro, J. M. – Ruiz, J., et al.: Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. *Ann Rheum Dis*, 2012, doi: 10.1136/annrheumdis-2012-201324.
- 8 Smolen, J. S. – Han, C. – Bala, M., et al.: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed sub-analysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis Rheum*, 2005, 52, s. 1020–1030.
- 9 McQueen, F. – Naredo, E.: The 'disconnect' between synovitis and erosion in rheumatoid arthritis: a result of treatment or intrinsic to the disease process itself? *Ann Rheum Dis*, 2011, 70, s. 241–244.
- 10 Furst, D. E. – Keystone, E. C. – Braun, J., et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. *Ann Rheum Dis*, 2012, 71 (dopl. II), s. i2–i45.

## Lékový profil: Spiriva Respimat

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

- 1 Slíva, J. – Votava, M.: *Farmakologie, Lékařské repetitorium*. Praha, Triton, 2011.
- 2 Keating, G. M.: Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. *Drugs*, 2012, 72, s. 273–300.
- 3 Vogelmeier, C. – Hederer, B. – Glaab, T. – Schmidt, H. – Rutten-van Mölken, M. P. – Beeh, K. M. – Rabe, K. F. – Fabbri, L. M.; POET-COPD Investigators: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *N Engl J Med*, 2011, 364 (12), s. 1093–1103.
- 4 Decramer, M. – Celli, B. – Tashkin, D. P., et al.: Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. *COPD*, 2004, 1, s. 303–312.
- 5 Decramer, M. – Celli, B. – Kesten, S. – Lystig, T. – Mehra, S. – Tashkin, D. P.: Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. *Lancet*, 2009, 374, s. 1171–1178.
- 6 Celli, B. – Decramer, M. – Kesten, S. – Liu, D. – Mehra, S. – Tashkin, D. P.: Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2009, 180, s. 948–955.
- 7 Hodder, R. – Pavia, D. – Lee, A. – Bateman, E.: Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(R) Soft Mist Inhaler in COPD. *Int J Chron Obstruct Pulmon Dis*, 2011, 6, s. 245–251.
- 8 Beeh, K. M. – Vogelmeier, C. – Rutten-van Mölken, M. P. M. H. – Rabe, K. F. – Glaab, T. – Rühmkorf, F. – Schmidt, H. – Fabbri, L. M.: Tiotropium vs salmeterol in GOLD II and maintenance-naïve COPD patients: Subgroup analyses of POET-COPD trial [abstract no. P251], 21<sup>st</sup> Annual Congress of the European Respiratory Society, 24.–28. září 2011, Amsterdam.
- 9 Tonnel, A. B. – Perez, T. – Grosbois, J. M. – Verkindre, C. – Bravo, M.

- L. – Brun, M.; TIPHON study group: Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. *Int J Chron Obstruct Pulmon Dis*, 2008, 3 (2), s. 301–310.
- 10 Casaburi, R. – Briggs, D. D. Jr. – Donohue, J. F. – Serby, C. W. – Menjoge, S. S. – Witek, T. J. Jr.: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. *Chest*, 2000, 118 (5), s. 1294–1302.
- 11 van Noord, J. A. – Bantje, T. A. – Eland, M. E. – Korducki, L. – Cornelissen, P. J.: A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. *Thorax*, 2000, 55 (4), s. 289–294.
- 12 Calverley, P. M. – Lee, A. – Towse, L. – van Noord, J. – Witek, T. J. – Kelsen, S.: Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. *Thorax*, 2003, 58 (10), s. 855–860.
- 13 Souhrn údajů o přípravku Spiriva, 16. 4. 2012.
- 14 Global Strategy for Diagnosis, Management, and Prevention of COPD, prosinec 2011, <http://www.goldcopd.org/>.

## Dabigatran etexilát – orální inhibitor trombinu

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Hankey, G. J. – Eikleboom, J. W.: Dabigatran etexilate. A new oral thrombin inhibitor. *Circulation*, 2011, 123, s. 1436–1450.
- 2 Eriksson, B. I. – Smith, H. – Yasothan, U. – Kirkpatrick, P.: Dabigatran etexilate. *Nature Reviews Drug Discovery*, 2008, 7, s. 557–558.
- 3 Eriksson, B. I. – Dahl, O. E. – Rosencher, N. – Kurth, A. A. – Van Dijk, C. N. – Frostick, S. P. – Kälebo, P. – Christiansen, A. V. – Hantel, S. – Hettiarachchi, R. – Schnee, J. – Buller, H. J. – the RE-MODEL Study Group: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. *Journal of Thrombosis and Haemostasis*, 2007, 5, s. 2178–2185.
- 4 Eriksson, B. I. – Dahl, O. E. – Rosencher, N. – Kurth, A. A. – van Dijk, C. N. – Frostick, S. P. – Prins, M. H. – Hettiarachchi, R. – Hanitel, S. – Schnee, J. – Büller, H. R. – the RE-NOVATE Study Group: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet*, 2007, 370, s. 949–956.
- 5 Ericsson, B. I. – Dahl, O. E. – Huo, M. H. – Kurth, A. A. – Hanitel, S. – Hermansson, K. – Schnee, J. M. – Friedman, R. J. – the RE-NOVATE II Study Group: Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II\*). *Thrombosis and Haemostasis*, 2011, 105, s. 721–729.
- 6 Eriksson, B. I. – Quinlan, D. J. – Eikelboom, J. W.: Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. *Annual Review of Medicine*, 2011, 62, s. 41–57.
- 7 Ginsberg, J. S. – Davidson, B. L. – Comp, P. C. – Francis, C. W. – Friedman, R. J. – Huo, M. H. – Lieberman, J. R. – Muntz, J. E. – Raskob, G. E. – Clements, M. L. – Hanitel, S. – Schnee, J. M. – Caprini, J. A.: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. *Journal of Arthroplasty*, 2009, 24, s. 1–9.
- 8 Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S. – Eikelboom, J. – Oldgren, J. – Parekh, A. – Pogue, J. – Reilly, P. A. – Themeles, E. – Varro-ne, J. – Wang, S. – Alings, M. – Xaver, D. – Zhu, J. – Diaz, R. – Lewis, B. S. – Darius, H. – Diener, H.-C. – Joyner, D. C. – Wallentin, L. – the RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. *New England Journal of Medicine*, 2009, 361, s. 1139–1151.
- 9 Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S. – Reilly, P. A. – Wallentin, L.: Newly identified events in the RE-LY trial. *New England Journal of Medicine*, 2010, 363, s. 1875–1876.
- 10 Healey, J. S. – Eikelboom, J. – Douketis, J. – Wallentin, L. – Oldgren, J. – Yang, S. – Themeles, E. – Heidbuchel, H. – Avezum, A. – Reilly, P. – Connolly, S. J. – Yusuf, S. – Ezekowitz, M.: Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: Results from the RE-LY randomized trial. *Circulation*, published online before print June 14, 2012, doi: 10.1161.
- 11 Oldgren, J. – Budaj, A. – Granger, C. B. – Khder, Y. – Roberts, R. – Siegbahn, A. – Tijssen, J. G. P. – Van de Werf, F. – Wallentin, L. – RE-DEEM Investigators: Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. *European Heart Journal*, 2011, 32, s. 2781–2789.

## Léčba periferní neuropatické bolesti – možnosti lokální terapie

MUDr. Jan Lejško ARK, Centrum léčby bolesti, FN Plzeň

- 1 Treede, R. D. – Jensen, T. S., et al.: Redefinition of neuropathic pain and a grading system for clinical use: consensus statement on clinical and research diagnostic criteria. *Neurology*, 2008, 70, s. 1630–1635.
- 2 Attal, N. – Cruccu, G. – Baron, R. – Haanpää, M. – Hansson, P. – Jensen, T. S. – Nurmikko, T.: EFNS guidelines on pharmacological treatment of neuropathic pain: 2009 revision. *Eur J Neurol*, 2009, 13, s. 1153–1169.
- 3 Farrar, J. – Young, J. P. Jr. – La Moreaux, R. – Werth, J. L. – Poole, R. M.: Clinical importance of chronic changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain*, 2001, 94, s. 149–158.
- 4 Rowbotham, M. C. – Davies, P. S. – Verkorenpinck, C., et al.: Lidocain patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. *Pain*, 1996, 65, s. 39–44.

# Kardiometabolické následky běžné dětské obezity

MUDr. Zlatko Marinov Dětské obezitologické centrum, FN Motol a 2. LF UK, Praha

- 1 Fontaine, K. R. – Redden, D. T. – Wang, C., et al.: Years of life lost due to obesity. *JAMA*, 2003, 289 (2), s. 187–931.
- 2 Horakova, D. – Stejskal, D. – Pastucha, D., et al.: Potential markers of insulin resistance in healthy vs obese and overweight subjects. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2010, 154 (3), s. 245–250.
- 3 Vignerová, J. – Riedlová, J. – Bláha, P., et al.: 6. celostátní antropologický výzkum dětí a mládeže 2001. Česká republika. Souhrnné výsledky. PfF UK, SZÚ, Praha, 2006, s. 238.
- 4 Pastucha, D. – Hyjánek, J. – Horáková, D.: Hypertenze dětského věku a její vztah k inzulinové rezistenci. *Pediatric pro praxi*, 2007, 8, s. 237–239.
- 5 Lobstein, T. – Jackson-Leach, R.: Estimated burden of paediatric obesity and co-morbidities in Europe. Part 2. Numbers of children with indicators of obesity-related disease. *Int J Pediatr Obes*, 2006, 1 (1), s. 33–41.
- 6 Krásničanová, H.: Vztahy mezi tělesnou hmotností a skeletální a sexuální maturací. Stav výživy a biologický věk – vybrané auxologické aspekty. *Postgraduální medicína*, 2010, příloha 2, s. 52–60.
- 7 Cykle, E. E. – Rodriguez, C. – Walker-Thurmond, K. – Thun, M. J.: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med*, 2003, 348 (17), s. 1625–1638.
- 8 Reaven, G. M.: The metabolic syndrome: is this diagnosis necessary? *Am J Clin Nutr*, 2006, 83, s. 1237–1247.
- 9 Zimmet, P. – Alberti, K. G. – Kaufman, F., et al.: The metabolic syndrome in children and adolescents—an IDF consensus report. *Pediatr Diabetes*, 2007, 8 (5), s. 299–306.
- 10 Simmons, R. K. – Alberti, K. G. – Gale, E. A. – Colagiuri, S., et al.: The metabolic syndrome: useful concept or clinical tool? *Diabetologia*, 2010, 53 (4), s. 600–605.
- 11 Steinberger, J. – Daniels, S. R. – Eckel, R. H., et al.: Progress and challenges in metabolic syndrome in children and adolescents. *Circulation*, 2009, 119 (4), s. 628–647.
- 12 Marinov, Z. – Čepová, J.: Metabolické parametry pacientů dětské obezitologické ambulance. *ČS pediatrie*, 2010, 2, s. 72–78.
- 13 Vitáriušová, E. – Košťálová, L. – Pribilincová, Z., et al.: Výskyt metabolického syndrómu a jeho komponentov u obézných dětí. *ČS pediatrie*, 2010, 2, s. 55–61.
- 14 Marinov, Z. – Pastucha, D.: *Praktická dětská obezitologie*. Grada publishing, Praha, 2012.

# Fomepizol – antidotum při otravě metanolem a etylenglykolem

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Bronstein, A. C. – Spyker, D. A. – Cantilena, L. S. – Green, J. L. – Rummack, B. H. – Dart, R. C.: 2010 Annual Report of the American Association of Poison Control Centers 'National Poison Data System (NPDS): 28<sup>th</sup> Annual Report. *Clinical Toxicology*, 2011, 49, s. 910–941.
- 2 Paasma, R. – Hovda, K. E. – Tikkerberi, A. – Jacobsen, D.: Methanol mass poisoning in Estonia: Outbreak in 154 patients. *Clinical Toxicology*, 2007, 45, s. 152–157.
- 3 Gee, P. – Martin, E.: Toxic cocktail. Methanol poisoning in a tourist to Indonesia. *Emergency Medicine Australasia*, 2012, 24, s. 451–453.
- 4 Brahmi, N. – Blel, Y. – Abidi, N. – Kouraichi, N. – Thabet, H. – Bednili, A. – Mamou, M.: Methanol poisoning in Tunisia: Report of 16 cases. *Clinical Toxicology*, 2007, 45, s. 717–720.
- 5 Bennett, I. L. – Cary, F. H. – Mitchell, G. L. – Cooper, M. N.: Acute methyl alcohol poisoning: a review based on experiences in an outbreak of 323 cases. *Medicine*, 1953, 32, s. 431–463.
- 6 Garner, C. D. – Lee, E. W. – Terzo, T. S. – Louis-Ferdinand, R. T.: Role of retinal metabolism in methanol-induced retinal toxicity. *Journal of Toxicology and Environmental Health*, 1995, 44, s. 43–56.
- 7 Hantson, P. – Wittebole, X. – Haufroid, V.: Ethanol therapy for methanol poisoning: duration and problems. *European Journal of Emergency Medicine*, 2002, 9, s. 278–279.
- 8 Brent, J.: Fomepizole for ethylene glycol and methanol poisoning. *New England Journal of Medicine*, 2009, 360, s. 2216–2223.
- 9 Barceloux, D. G. – Bond, G. R. – Krenzelok, E. P. – Cooper, H. – Vale, J. A.: AACT Ad Hoc Committee on the Treatment Guidelines for Methanol Poisoning. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. *Journal of Toxicology – Clinical Toxicology*, 2002, 40, s. 415–446.
- 10 Hovda, K. E. – Andersson, K. S. – Urdal, P. – Jacobsen, D.: Methanol and formate kinetics during treatment with fomepizole. *Clinical Toxicology*, 2005, 43, s. 221–227.
- 11 Hovda, K. E. – Froyskov, S. – Gudmundsdottir, H. – Rudberg, N. – Jacobsen, D.: Fomepizole may change indication for hemodialysis in methanol poisoning: prospective study in seven cases. *Clinical Nephrology*, 2005, 64, s. 190–197.
- 12 Brent, J. – McMartin, K. – Phillips, S. – Aaron, C. – Kulig, K.: Fomepizole for the treatment of methanol poisoning. *New England Journal of Medicine*, 2001, 344, s. 424–429.
- 13 Jacobsen, D. – Barron, S. K. – Sebastian, C. S. – Blomstrand, R. – McMartin, K. E.: Non-linear kinetics of 4-methylpyrazole in healthy human subjects. *European Journal of Clinical Pharmacology*, 1989, 37, s. 599–604.
- 14 Guo, C. – Cenac, T. A. – Li, Y. – McMartin, K. E.: Calcium oxalate, and not other metabolites, is responsible for the renal toxicity of ethylene glycol. *Toxicology Letters*, 2007, 173, s. 8–16.
- 15 Clay, K. L. – Murphy, R. C.: On the metabolic acidosis of ethylene glycol intoxication. *Toxicology and Applied Pharmacology*, 1977, 39, s. 39–49.
- 16 Hall, T. L.: Fomepizole in the treatment of ethylene glycol poisoning. *Canadian Journal of Emergency Medicine*, 2002, 4, s. 199–204.
- 17 Barceloux, D. G. – Krenzelok, E. P. – Olson, K. – Watson, W.: American Academy of Clinical Toxicology practice guidelines on the treatment of ethylene glycol poisoning. *Journal of Toxicology – Clinical Toxicology*, 1999, 37, s. 537–560.
- 18 Brent, J. – McMartin, K. – Phillips, S. – Burkhart, Kl. K. – Donovan, J. W. – Wells, M. – Kulig, K.: Fomepizole for the treatment of ethylene glycol poisoning. *New England Journal of Medicine*, 1999, 340, s. 832–838.